| 刘艳霞,张聪,韩霞,等.老年冠心病患者ApoE基因多态性对瑞舒伐他汀疗效的影响[J].中国临床保健杂志,2020,23(2):188-190. |
| 老年冠心病患者ApoE基因多态性对瑞舒伐他汀疗效的影响 |
| Effect of ApoE gene polymorphism on the efficacy of rosuvastatin in elderly patients with coronary heart disease |
| 投稿时间：2019-11-17 |
| DOI：10.3969/J.issn.1672-6790.2020.02.011 |
| 中文关键词: 冠心病 多态现象,遗传 瑞舒伐他汀钙 老年人 |
| 英文关键词: Coronary heart disease Polymorphism,genetic Rosuvastatin calcium Aged 〖FL |
| 基金项目:国家自然科学基金面上项目(81670267)；中国博士后科学基金面项目(2018M633697)；辽宁省自然科学基金指导计划项目(20180550534)；辽宁省自然科学基金指导计划项目(2019ZD1042) |
|
| 摘要点击次数: 5454 |
| 全文下载次数: 5277 |
| 中文摘要: |
| 目的 探讨ApoE基因多态性对老年冠心病患者应用瑞舒伐他汀调脂疗效的影响。方法 选取年龄≥65岁的老年冠心病患者54例为研究对象,给予瑞舒伐他汀口服治疗(10 mg,1次/天),疗程为3个月。用药前通过测序法检测患者他汀类药物ApoE基因多态性,观察治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)等血脂水平变化及不良反应。结果 应用瑞舒伐他汀治疗老年冠心病患者,E2/E3及E3/E3基因型降低LDL-C疗效优于E3/E4基因型患者(P＜0.05)；E3/E3基因型患者TC、TG降低水平优于E2/E3及E3/E4基因型患者；对于E3/E4基因型患者疗效较差。不同基因型患者治疗后肾功能及肌肉损害差异无统计学意义(P＞0.05)。结论 瑞舒伐他汀对于携带E2/E3、E3/E3基因的老年冠心病患者疗效更好,优于E3/E4基因型。 |
| 英文摘要: |
| Objective To investigate the effect of ApoE gene polymorphism on the efficacy of rosuvastatin in the elderly patients with coronary heart disease.Methods 54 elderly patients with coronary heart disease aged 65 years and older were selected as the study subjects.Rosuvastatin was given orally at 10mg/day for 3 months.The ApoE gene polymorphism of statins was detected by sequencing before administration.Changes in blood lipids and adverse reactions of Total cholesterol (TC),Triglyceride (TG),Low density lipoprotein (LDL-C) before and after treatment were observed.Results The E2/E3 and E3/E3 genotypes had better effect on LDL-C reduction in elderly patients with coronary heart disease using rosuvastatin than those with E3/E4 genotypes (P<0.05).Patients with E3/E3 genotype had lower TC and TG levels than those with E2/E3 and E3/E4 genotypes.The efficacy of rosuvastatin in elderly patients with E3/E4 genotype was poor.There was no significant difference in renal function and muscle damage among patients with different genotype after treatment (P>0.05).Conclusion The efficacy of rosuvastatin in elderly patients with coronary heart disease with E2/E3 and E3/E3 genes is better than that of E3/E4 genotype. |
|
查看全文
|
| 关闭 |